These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 17716944

  • 1. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S, Dalpke A, Heeg K.
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [Abstract] [Full Text] [Related]

  • 2. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P, Sukumaran B, Saxena S, Madhubala R.
    Vaccine; 2004 Aug 13; 22(23-24):3053-60. PubMed ID: 15297055
    [Abstract] [Full Text] [Related]

  • 3. CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii.
    Kringel H, Dubey JP, Beshah E, Hecker R, Urban JF.
    Vet Parasitol; 2004 Aug 13; 123(1-2):55-66. PubMed ID: 15265571
    [Abstract] [Full Text] [Related]

  • 4. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P, Pandya J, Mehta J, Sukumaran B, Madhubala R.
    FEMS Immunol Med Microbiol; 2004 Oct 01; 42(2):241-8. PubMed ID: 15364110
    [Abstract] [Full Text] [Related]

  • 5. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N, Mukherjee S, Das L, Das PK.
    Eur J Immunol; 2003 Jun 01; 33(6):1508-18. PubMed ID: 12778468
    [Abstract] [Full Text] [Related]

  • 6. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection.
    Sánchez VR, Pitkowski MN, Fernández Cuppari AV, Rodríguez FM, Fenoy IM, Frank FM, Goldman A, Corral RS, Martin V.
    Exp Parasitol; 2011 Aug 01; 128(4):448-53. PubMed ID: 21554876
    [Abstract] [Full Text] [Related]

  • 7. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii.
    Saavedra R, Leyva R, Tenorio EP, Haces ML, Rodríguez-Sosa M, Terrazas LI, Hérion P.
    Parasite Immunol; 2004 Feb 01; 26(2):67-73. PubMed ID: 15225293
    [Abstract] [Full Text] [Related]

  • 8. CpG-ODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice.
    Ribeiro DP, Freitas MM, Cardoso MR, Pajuaba AC, Silva NM, Mineo TW, Silva JS, Mineo JR, Silva DA.
    Vaccine; 2009 Apr 28; 27(19):2570-9. PubMed ID: 19428863
    [Abstract] [Full Text] [Related]

  • 9. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.
    Barrier M, Lacroix-Lamandé S, Mancassola R, Auray G, Bernardet N, Chaussé AM, Uematsu S, Akira S, Laurent F.
    J Infect Dis; 2006 May 15; 193(10):1400-7. PubMed ID: 16619188
    [Abstract] [Full Text] [Related]

  • 10. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.
    Eur J Immunol; 2006 Jan 15; 36(1):12-20. PubMed ID: 16323249
    [Abstract] [Full Text] [Related]

  • 11. Protective effect of vaccination with Toxoplasma lysate antigen and CpG as an adjuvant against Toxoplasma gondii in susceptible C57BL/6 mice.
    El-Malky M, Shaohong L, Kumagai T, Yabu Y, Noureldin MS, Saudy N, Maruyama H, Ohta N.
    Microbiol Immunol; 2005 Jan 15; 49(7):639-46. PubMed ID: 16034207
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ.
    J Leukoc Biol; 2000 Oct 15; 68(4):455-63. PubMed ID: 11037965
    [Abstract] [Full Text] [Related]

  • 15. Immunostimulatory CpG-oligodeoxynucleotides (CpG-ODN) induce early hepatic injury, but provide a late window for protection against endotoxin-mediated liver damage.
    Slotta JE, Scheuer C, Menger MD, Vollmar B.
    J Hepatol; 2006 Mar 15; 44(3):576-85. PubMed ID: 16310279
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adjuvant effects of bacillus Calmette-Guerin DNA or CpG-oligonucleotide in the immune response to Taenia solium cysticercosis vaccine in porcine.
    Guo YJ, Wu D, Wang KY, Sun SH.
    Scand J Immunol; 2007 Dec 15; 66(6):619-27. PubMed ID: 18021362
    [Abstract] [Full Text] [Related]

  • 18. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ, Blackwell JM.
    Infect Immun; 1999 Aug 15; 67(8):3719-26. PubMed ID: 10417129
    [Abstract] [Full Text] [Related]

  • 19. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
    Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA.
    J Control Release; 2004 May 31; 97(1):1-17. PubMed ID: 15147800
    [Abstract] [Full Text] [Related]

  • 20. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J, Adamsson J, Harandi AM.
    Scand J Immunol; 2008 May 31; 67(5):431-40. PubMed ID: 18298617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.